Menu Search
Equities

Zhejiang Shapuaisi Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
603168:SHH

Zhejiang Shapuaisi Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.38
  • Today's Change0.02 / 0.27%
  • Shares traded3.72m
  • 1 Year change+7.42%
  • Beta0.7943
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Zhejiang Shapuaisi Pharmaceutical Co Ltd's revenues fell -24.96% from 644.97m to 483.96m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 25.41m to a loss of 123.44m.
Gross margin50.11%
Net profit margin-13.78%
Operating margin-13.69%
Return on assets-3.08%
Return on equity-3.94%
Return on investment-3.66%
More ▼

Cash flow in CNYView more

In 2024, cash reserves at Zhejiang Shapuaisi Pharmaceutical Co Ltd fell by 272.88m. Cash Flow from Financing totalled 37.11m or 7.67% of revenues. In addition the company generated 25.67m in cash from operations while cash used for investing totalled 335.66m.
Cash flow per share--
Price/Cash flow per share--
Book value per share4.31
Tangible book value per share2.80
More ▼

Balance sheet in CNYView more

Zhejiang Shapuaisi Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 15.87%, a higher figure than the previous year's 7.33%.
Current ratio1.16
Quick ratio0.8289
Total debt/total equity0.1887
Total debt/total capital0.1587
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.